1623 results for "LSD"
Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts
Journal of Psychoactive Drugs – March 01, 2025
Summary
Remarkably, 86.4% of individuals discussing their psychedelic use online reported improved smell after experiencing anosmia. Analyzing 125 posts, a significant 50.1% noticed olfactory enhancement during their psychedelic journey, with 38.8% experiencing benefits lasting over a day. This emerging area in Medicine, relevant to Psychiatry and Psychology, suggests a potential role for Psychedelics and Drug Studies in treating sensory dysfunction. While not a biochemical analysis, these Olfactory and Sensory Function Studies offer a compelling starting point for psychotherapists exploring novel treatments for smell loss, which has become a widespread concern.
Abstract
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years,...
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Addiction – January 30, 2025
Summary
Psilocybin-assisted treatment for alcohol use disorder shows the strongest evidence among major psychedelic treatments. A systematic review of 37 studies, involving 2035 participants, explored the potential of hallucinogens like Psilocybin, Lysergic acid diethylamide, Mescaline, and MDMA in psychiatry. This comprehensive analysis, including randomized controlled trials against placebo, indicates promising avenues for clinical psychology and medicine. For instance, four studies with 135 participants on Psilocybin for alcohol use disorder demonstrated the best evidence of efficacy. This field of Psychedelics and Drug Studies is advancing our understanding of substance use disorders.
Abstract
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol u...
The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
Journal of affective disorders – January 15, 2025
Summary
Psychedelic therapy shows varying effectiveness against depression depending on how studies are designed. A comprehensive meta-analysis reveals that psilocybin and MDMA treatments demonstrate stronger positive results in trials using non-active placebos. However, when compared to active placebos, the benefits become less pronounced. Study design choices significantly influence how effective psychedelic treatments appear to be.
Abstract
Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to exam...
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Clinical Pharmacology & Therapeutics – September 30, 2024
Summary
Genetic variations significantly influence how individuals respond to **psychedelics**, a critical insight for future **medicine**. **Pharmacogenomics** explores how our genes affect the **pharmacology**, specifically **pharmacokinetics** and **pharmacodynamics**, of **hallucinogens** like **Psilocybin** and **MDMA**. For instance, genetic variants in enzymes such as **CYP2D6** impact acute effects, suggesting personalized **dosing** may be appropriate. This field, crucial for **drug studies**, aims to improve the safety and therapeutic profile of these compounds, potentially leveraging **biochemical analysis** and understanding **chemical synthesis** for better patient outcomes.
Abstract
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for whic...
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response
Journal of Psychopharmacology – September 20, 2024
Summary
Remarkably, relaxation during psychedelic-assisted therapy, not mystical experiences, best predicted significant antidepressant effects. Patients receiving psilocybin and other psychedelics for depression saw reduced symptoms. Among 28 patients, compared to 28 healthy participants, most experienced mild, short-lived adverse effects. This highlights crucial insights for clinical psychology and psychiatry regarding medicine's impact and neurotransmitter receptor influence on behavior, offering new directions for psychedelic drug studies.
Abstract
Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this progra...
Adverse Events in Studies of Classic Psychedelics
JAMA Psychiatry – September 04, 2024
Summary
Healthy participants experienced zero serious adverse effects from classic hallucinogens like psilocybin. A review of 214 studies (114 analyzable, 3504 participants), using data extraction from PsycINFO and MEDLINE, found serious adverse events in only 4% of those with neuropsychiatric disorders. Nonserious adverse effects needing medicine were similarly rare. While generally well-tolerated in clinical psychology and psychiatry, understanding these psychedelics' neurotransmitter receptor influence on behavior is vital for new populations in drug studies, especially for compounds from chemical synthesis and alkaloids.
Abstract
Importance A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its a...
Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Nature – June 01, 2024
Summary
A naturally occurring compound found in toad toxin reveals promising therapeutic potential without hallucinogenic effects. Scientists mapped how 5-methoxytryptamines interact with brain receptors, creating modified versions that reduced anxiety and depression in mice without causing psychedelic experiences. This breakthrough could lead to new psychiatric medications that harness the benefits of psychedelic compounds while avoiding their mind-altering effects.
Abstract
Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorde...
Early-onset alcohol, tobacco, and illicit drug use with age at onset of hypertension: a survival analysis.
Social psychiatry and psychiatric epidemiology – July 01, 2024
Summary
Starting substance use before age 18 can accelerate the onset of hypertension by up to several years. Analysis of 19,000+ adults revealed that early exposure to alcohol, tobacco, and marijuana significantly increased the risk of developing high blood pressure at a younger age. Those who began using substances in their teens faced up to 85% higher risk of early hypertension compared to non-users.
Abstract
To examine the associations of age when first substance use and early-onset substance use before age 18 with age at onset (AAO) of hypertension. Th...
Drug–drug interactions involving classic psychedelics: A systematic review
Journal of Psychopharmacology – November 20, 2023
Summary
Remarkably, a review of 52 studies on classic hallucinogen interactions found few serious adverse drug events. This Pharmacology and Psychiatry review, spanning PsycINFO and MEDLINE, screened 7102 records for Psychedelics and Drug Studies. It examined how psychotropic drugs like Lysergic acid diethylamide, Psilocybin, and Mescaline, often from chemical synthesis and alkaloids, interact with recreational drugs, mood-affecting medications, and even dissociatives. Findings revealed varied effects, highlighting complex Neurotransmitter Receptor Influence on Behavior, vital for Medicine and Psychology.
Abstract
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltry...
Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City
Journal of Psychoactive Drugs – August 21, 2023
Summary
Summer significantly increases psychedelic use among nightclub and festival attendees. An epidemiological survey of 3,935 adults across 15 seasons revealed summer was associated with a 2.72 odds ratio for Lysergic acid diethylamide use and 1.65 odds ratio for Psilocybin. These Psychedelics and Drug Studies findings highlight seasonal hallucinogen consumption patterns. Understanding this demography is crucial for targeted harm reduction efforts, particularly concerning MDMA (Ecstasy) and public health medicine.
Abstract
Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival atten...
Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel.
Harm reduction journal – August 09, 2023
Summary
Israeli nature rave parties reveal a fascinating intersection of music culture and public health. At these outdoor celebrations, attendees show strong support for harm reduction strategies while using various substances. A survey of 1,200+ partygoers found cannabis as the most common substance (62%), followed by psychedelics. While participants supported safety measures like drug testing, turning attitudes into actions proved challenging. The findings highlight opportunities to enhance safety at these events.
Abstract
Few studies have analyzed harm reduction behaviors and attitudes among rave party attendees. Since the late 1980s, there has been a large Israeli r...
Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists.
ACS chemical neuroscience – August 02, 2023
Summary
Psychedelic compounds work through unique molecular pathways in the brain, specifically targeting the 5-HT2A receptor. Scientists examined how different psychedelic molecules activate this receptor through two distinct cellular pathways - miniGαq and β-arrestin signaling. The research revealed that chemical properties, particularly fat-solubility, influence how strongly these compounds bind and activate neural pathways.
Abstract
Serotonergic psychedelics are described to have activation of the serotonin 2A receptor (5-HT2A) as their main pharmacological action. Despite thei...
Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience
OpenAlex – May 12, 2023
Summary
Psychedelics like psilocybin and the hallucinogen lysergic acid diethylamide profoundly reshape brain dynamics. Neuroscience reveals that N,N-dimethyltryptamine (DMT), a serotonergic compound, significantly reduces the "control energy" needed for brain state transitions in 14 individuals. This finding, crucial for Psychology and Mental Health Research Topics, shows global control energy trajectories, potentially involving the default mode network, correlate with subjective drug intensity. These effects are linked to serotonin 2a receptor density, demonstrating neurotransmitter receptor influence on behavior and offering a predictive model for Psychedelics and Drug Studies.
Abstract
Abstract Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, su...
The Global Distribution and Epidemiology of Psychoactive Substance Use and Injection Drug Use Among Street-Involved Children and Youth: A Meta-Analysis.
Substance use & misuse – January 01, 2023
Summary
A global analysis reveals that tobacco and cannabis are the most commonly used substances among young people living on streets. Higher rates of psychoactive substance use strongly correlate with experiences of violence, homelessness, and risky sexual behaviors. Males with family history of substance use face greater risks. The data shows age-specific patterns: while meth and cannabis use increase with age, tobacco and cocaine use typically decrease.
Abstract
Background: Globally, street-involved children and youth (SICY) who work and live on/of the streets are at higher risk of increased psychoactive su...
Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
Journal of Psychoactive Drugs – October 11, 2022
Summary
Psychedelics are experiencing a profound resurgence in Psychiatry. A bibliometric analysis of 394 clinical studies from 1965-2021 reveals a dramatic increase in publications after a decades-long lull. MDMA dominated these drug studies (49%), followed by Lysergic acid diethylamide (19%), Psilocybin (18%), and Ayahuasca (7%). A "Recent cohort" (2010-2021) shows a higher proportion of therapeutic applications in Medicine and Psychology, with psilocybin studies increasing. Mescaline research saw a proportional decrease. This highlights the evolving focus on these powerful hallucinogens.
Abstract
Following a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as psychiatric treatments. The aca...
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Molecules – April 13, 2022
Summary
For thousands of years, psychedelics like psilocybin and lysergic acid diethylamide held spiritual and medicinal value in ancient cultures. Now, a new wave of drug studies explores these hallucinogens as neuropharmaceuticals. Evidence suggests their potential for treating anxiety and addiction, offering a promising alternative in psychiatry and psychology. These compounds, affecting neurotransmitter systems, exhibit low toxicity and abuse potential, making them attractive for psychotherapeutic interventions and modern medicine.
Abstract
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Os...
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing.
British journal of clinical pharmacology – June 16, 2025
Summary
Remarkably, tiny zebrafish are proving instrumental in understanding drug metabolism. A new workflow hypothesized that zebrafish embryos could rapidly identify human urine biomarkers for drugs of abuse and new psychoactive substances. By exposing zebrafish, then confirming findings with human microdosing and LC-HRMS/MS analysis, key human metabolites were successfully identified. This offers a quick, reliable method for predicting drug screening markers.
Abstract
The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabo...
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
Journal of Psychopharmacology – July 11, 2025
Summary
Compelling evidence suggests certain hallucinogens may aid smoking cessation. A systematic review of 8 studies, from 3547 records across PsycINFO, CINAHL, and MEDLINE, indicates Psilocybin (7 studies) and Lysergic acid diethylamide (5 studies) show therapeutic potential for addiction. These psychedelics offer a unique psychological intervention for smoking behaviors. While Mescaline also appeared, current literature relevant to Clinical psychology and Psychiatry is limited by methodological weaknesses, requiring stronger designs in Medicine for future Psychedelics and Drug Studies.
Abstract
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated ...
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.
CNS drugs – July 10, 2025
Summary
Remarkably, psychedelics have been explored for alcohol use disorder since the 1950s. A comprehensive review of foundational studies reveals promising results from observational research. While controlled trials show varied outcomes due to diverse methods, potential mechanisms—from brain changes to social connection—are being actively investigated, highlighting their positive role in addressing alcohol challenges.
Abstract
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lyserg...
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
Neuron – July 15, 2025
Summary
Psychedelics, known for their hallucinogen properties, show surprising potential. Research explored 41 psychedelics, finding they broadly interact with G-protein-coupled receptors, including serotonin receptors and dopamine receptors. This comprehensive profiling revealed these compounds activate multiple targets, suggesting their effects, including therapeutic benefits, stem from complex interactions beyond a single receptor. This broad engagement highlights their diverse pharmacological actions.
Abstract
The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-...
Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
The American journal of drug and alcohol abuse – November 01, 2016
Summary
Over a third of young adults at NYC electronic dance music events have used novel psychoactive substances. A survey of 682 attendees at nightclubs and festivals found 35.1% lifetime use. Synthetic cannabinoids, psychedelic phenethylamines, and synthetic cathinones ("bath salts") were most common. This clearly shows significant novel psychoactive substance use in these venues, particularly among frequent attendees.
Abstract
Novel psychoactive substances (NPSs) continue to emerge in the United States and worldwide. Few epidemiological studies have examined the prevalenc...
Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus.
Pharmacology, biochemistry, and behavior – February 01, 1998
Summary
No Summary
Abstract
In the present investigation, the ability of two known hallucinogens, lysergic acid dimethylamide (LSD) and (-)-2,5-dimethoxy-4-methyl-amphetamine ...
Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys.
Pharmacology, biochemistry, and behavior – February 01, 1998
Summary
No Summary
Abstract
The discriminative stimulus properties of ibogaine were investigated in rats trained to discriminate phencyclidine (PCP; 2.0 mg/kg, I.P.) from sali...
Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
Journal of neurochemistry – December 01, 1996
Summary
No Summary
Abstract
Stable transfection of the human neuroblastoma cell line SH-SY5Y with the human 5-hydroxytryptamine2A (5-HT2A) or 5-HT2C receptor cDNA produced cel...
Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin.
The Journal of biological chemistry – June 21, 1996
Summary
No Summary
Abstract
Like other amine neurotransmitters that activate G-protein-coupled receptors, 5-hydroxytryptamine (5-HT) binds to the 5-HT2A receptor through the i...
Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.
Naunyn-Schmiedeberg's archives of pharmacology – June 01, 1990
Summary
No Summary
Abstract
In pigs, the serotonin-2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), 0.8 mg/kg, induced "psychotic" behaviour (e....
The effects of 8-hydroxy-2-(di-n-propylamino)tetralin and other serotonergic agonists on performance in a radial maze: a possible role for 5-HT1A receptors in memory.
Pharmacology, biochemistry, and behavior – August 01, 1987
Summary
No Summary
Abstract
A group of ten rats was trained to obtain food pellets in an 8-arm radial maze. The effects of pretreatment with (+)-Lysergic acid diethylamide (+)...
Local cerebral glucose utilisation following indoleamine- and piperazine-containing 5-hydroxytryptamine agonists.
Journal of neurochemistry – January 01, 1986
Summary
No Summary
Abstract
Substances with varying structural components have been shown to have 5-hydroxytryptamine (5-HT)-like properties in the CNS. In this study, putativ...
Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants.
Psychopharmacology – January 01, 1982
Summary
No Summary
Abstract
The serotonin syndrome, a behavioral response produced by the activation of serotonin receptors, and 3H-serotonin binding were examined after repea...
Dosing Psychedelics and MDMA.
Current topics in behavioral neurosciences – January 01, 2022
Summary
No Summary
Abstract
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, espec...
Human behavioral pharmacology of psychedelics.
Advances in pharmacology (San Diego, Calif.) – January 01, 2022
Summary
No Summary
Abstract
The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an ...
Psychedelics as Psychiatric Medications
OpenAlex – March 01, 2023
Summary
Psilocybin, a potent hallucinogen, effectively alleviates distress in individuals with cancer-related depression and anxiety. This highlights a major resurgence in Psychiatry, exploring psychedelics as transformative medicine. Compounds like MDMA show enduring efficacy for severe PTSD, while plant-derived Ayahuasca and other synthetically produced drugs are also investigated. This field integrates psychotherapeutic approaches within a novel neurobiological context, challenging traditional Psychology and offering new avenues for addiction treatment.
Abstract
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s...
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress
International Review of Psychiatry – July 04, 2018
Summary
Psilocybin, a powerful hallucinogen, shows remarkable potential in psychiatry, offering rapid and sustained relief from cancer-related distress. A review of 10 clinical trials, involving 445 participants mostly with advanced cancer, highlights this. Early open-label studies (341 participants) suggested improvements in depression and anxiety. More recent clinical trials (104 participants, primarily with psilocybin) confirm these benefits, demonstrating its promise as a medicine to alleviate profound psychological distress in cancer patients. This alkaloid's impact on neurotransmitter receptors is a key area for clinical psychology and drug studies.
Abstract
Cancer is highly prevalent and one of the leading causes of global morbidity and mortality. Psychological and existential suffering is common in ca...
Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review
Pharmaceuticals – August 12, 2021
Summary
Psychedelics show promise for severe depression, a clinical challenge. A systematic review, analyzing 10 papers from databases like MEDLINE and Cochrane Library, explores the potential of hallucinogens like Psilocybin and Lysergic acid diethylamide in psychiatry. Focusing on pharmacology and neurotransmitter receptor influence on behavior, the review found Psilocybin and DMT significantly correlated with reduced depression symptom intensity. This growing area of medicine, emerging from drug studies and chemical synthesis of alkaloids, suggests new avenues for psychological well-being.
Abstract
Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently...
Patterns of simultaneous polysubstance use in drug using university students
Human Psychopharmacology Clinical and Experimental – June 01, 2006
Summary
Alcohol frequently initiates polysubstance dependence, dictating drug consumption sequence. Interviews with 149 university students revealed alcohol was consumed first when co-administered with drugs like cannabis, psilocybin (a hallucinogen), MDMA, or amphetamine. Alcohol intake also increased with cocaine or methylphenidate, and tobacco use rose. This complex drug pharmacology in a forensic toxicology context informs psychiatry, psychology, and medicine, guiding substance abuse treatment and outcomes by understanding neurotransmitter receptor influence on behavior.
Abstract
Abstract Simultaneous polysubstance use (SPU) is a common phenomenon, yet little is known about how various substances are used with one another. I...
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
Therapeutic Advances in Psychopharmacology – February 23, 2017
Summary
Psychotic episodes linked to the hallucinogen Ayahuasca are remarkably rare, even outside controlled settings. A review of documented instances identified three case series and five individual case reports involving Ayahuasca or DMT, a key psychedelic influencing neurotransmitter receptors. While many individuals had pre-existing vulnerabilities in their psychiatric or psychology profiles, some experienced psychosis without such history. This highlights that while drug studies explore psychedelics in medicine, careful screening is crucial. Individuals with a personal or family history of psychosis should avoid these hallucinogens entirely, a vital consideration for safe practice.
Abstract
Ayahuasca is a hallucinogen brew traditionally used for ritual and therapeutic purposes in Northwestern Amazon. It is rich in the tryptamine halluc...
Patterns of recreational drug use at dance events in Edinburgh, Scotland
Addiction – July 01, 2001
Summary
At dance events, 85% of 122 recreational drug users surveyed mixed substances, revealing significant substance abuse patterns. Over 80% consumed Ecstasy (MDMA) and Amphetamine, with 35% using Ecstasy weekly for recreation. Hallucinogens like Psilocybin and Lysergic acid diethylamide were also reported. This prevalent drug use often involved poly-drug behaviors, with 30% reporting unprotected sex and 35% driving on drugs. Such findings from Forensic Toxicology and Drug Analysis highlight critical public health and psychiatry concerns within music culture.
Abstract
Aims . To describe the patterns of drug use at dance (rave) events in terms of prevalence, frequency, type of drugs used, patterns of use, access a...
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Frontiers in Synaptic Neuroscience – August 21, 2020
Summary
A compelling new frontier in Medicine suggests psychedelics like psilocybin, a potent hallucinogen, could revolutionize Dementia treatment. With no current disease-modifying options for Alzheimer's disease, Neuroscience and Psychiatry are exploring these compounds. Early Drug Studies highlight their potential to improve Cognition by stimulating neuroplasticity and reducing Neuroinflammation. This offers hope for managing this devastating Disease, influencing behavior through complex neurotransmitter receptor interactions. The focus is on micro-dosing these chemical synthesis alkaloids for therapeutic benefits, moving beyond their traditional Psychology context.
Abstract
Currently, there are no disease-modifying treatments for Alzheimer's disease (AD) or any other dementia subtype. The renaissance in psychedelic res...
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Addiction Neuroscience – June 22, 2022
Summary
Psychedelics offer a compelling new frontier for substance use disorder, a global public health concern where current psychiatric treatments face challenges. Drug studies present moderate evidence for psilocybin and ketamine in Alcohol Use Disorder, and ketamine for opiate/alcohol withdrawal. THC preparations also aid cannabis/opioid withdrawal symptoms. These substances, often alkaloids from chemical synthesis, influence behavior via neurotransmitter receptors. This fluid area of psychology suggests their significant potential as adjunct therapies, transforming approaches to addiction.
Abstract
Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction h...
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study
Journal of Substance Use – July 30, 2010
Summary
Over 81% of hallucinogen users reported a profound spiritual experience, with over 90% linking classic psychedelics like Psilocybin and Lysergic acid diethylamide to accessing the unconscious mind. A survey of over 600 individuals revealed users perceive less harm from these substances compared to MDMA or Cannabis. Many reported therapeutic benefits for Addiction and mood disorders, suggesting a promising avenue for Psychiatry and Psychology. This highlights the potential for Neurotransmitter Receptor Influence on Behavior, suggesting deeper inquiry in Psychedelics and Drug Studies, extending beyond Cannabis and Cannabinoid Research.
Abstract
This study used a web-based questionnaire to investigate user perceptions of the benefits and harms of hallucinogenic drug use. Over 600 forms were...
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
Journal of Psychopharmacology – March 19, 2021
Summary
Almost a third of patients with major depressive disorder are non-responders to current antidepressants, a critical challenge in Psychiatry. Promisingly, fast-acting serotonergic hallucinogens like psilocybin, lysergic acid diethylamide, and ayahuasca demonstrate antidepressant and anxiety-reducing effects. Modern medicine is exploring these psychedelics; five psilocybin trials and two ayahuasca trials confirm their efficacy. Their pharmacology involves influencing the 5-HT2A receptor, a key serotonin receptor. These drug studies highlight their profound neurotransmitter receptor influence on behavior, offering new therapeutic avenues beyond traditional serotonin antagonists in Psychology.
Abstract
Major depressive disorder (MDD) is among the most prevalent mental health disorders worldwide, and it is associated with a reduced quality of life ...
Second and third year medical students’ self-reported alcohol and substance use, smoking habits and academic performance at a South African medical school
Health SA Gesondheid – September 18, 2019
Summary
Future healthcare professionals exhibit concerning substance use. An observational study of 171 medical students revealed 78.4% of second-years and 82.8% of third-years reported alcohol use. Cannabis use was reported by 22% and 24.1% respectively, with 1.8% also using Ecstasy. These descriptive statistics, including demographics, highlight a critical need for robust Substance Abuse Treatment and Outcomes, and Mental Health Treatment and Access, impacting clinical psychology and psychiatry, to support future practitioners in Medicine, addressing their own stress and burnout.
Abstract
Background: Health professional students frequently use alcohol and narcotics. The potential impact on academic performance and professional behavi...
Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
Psychological Medicine – November 04, 2020
Summary
Psychedelics like psilocybin and ayahuasca, potent hallucinogens, demonstrate substantial mental health benefits. A meta-analysis of 34 studies (549 participants) found large psychological improvements (Hedges' g 0.84-1.08) versus placebo in randomized controlled trials. These effects, potentially linked to neurotransmitter receptor influence on behavior, spanned psychiatry and clinical psychology, with moderation for clinical samples. No post-acute adverse effect was observed, advancing interest in these chemical synthesis and alkaloids for Psychedelics and Drug Studies.
Abstract
Abstract Background Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychologic...
Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019
Frontiers in Epidemiology – March 23, 2022
Summary
Asian females exhibit the highest past-year hallucinogen use (35.06%), over twice that of White males/females. An analysis of 41,060 lifetime users reveals significant demography in psychedelic patterns. Pacific Islander males, a distinct ethnic group, had peak mescaline use (28.27%). Black, Asian, and Multiracial individuals had greater odds (1.20–2.06) of recent hallucinogen use than White people. Females generally had lower odds, except for MDMA. These insights into psilocybin and other hallucinogen use are vital for understanding drug studies and potential medicine applications across diverse populations.
Abstract
Background The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use a...
Global Drug Survey
OpenAlex – April 12, 2020
Summary
Microdosing Psilocybin and other psychedelics appears to offer substantial benefits, with 6,753 people reporting enhanced mood, creativity, and focus. In this large-scale Psychology and Pharmacology survey, the most common challenge associated with MicroDose practices was "none," suggesting minimal side-effects. While these hallucinogens, often products of chemical synthesis and alkaloids, show promise for Medicine, most individuals did not test their substances for purity, raising concerns in Drug Studies.
Abstract
Background: Microdosing psychedelics – the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushr...
Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review
Psychoactives – July 03, 2024
Summary
Psilocybin, a hallucinogen, may offer a surprising protective effect against suicidal behavior, a key finding for clinical psychology and psychiatry. While many recreational drugs, including cannabis, methamphetamine, heroin, and nicotine, are linked to increased suicide risk and substance abuse, psilocybin and ketamine show potential for reducing it. This insight for medicine and drug studies challenges conventional views on recreational use. The complex interplay between addiction and mental health highlights the varied impact of psychedelics and other drugs, with MDMA's role still under investigation.
Abstract
Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the pre...
Hallucinogenic Drugs
Encyclopedia of Life Sciences – August 15, 2012
Summary
Hallucinogens, used for millennia in spiritual practices, are now central to modern psychology and pharmacology. Potent psychedelics like Lysergic acid diethylamide, Psilocybin, and Mescaline exert their powerful influence on behavior by primarily modulating serotonin neurotransmitter receptors, leading to profound perceptual and cognitive shifts. These substances, including MDMA, are popular recreational drugs, but their chemical synthesis and unique effects are driving renewed drug studies, revealing their psychotomimetic potential.
Abstract
Abstract Hallucinogens constitute one of the oldest classes of drugs used by humanity, often in the context of spiritual practices. Classic halluci...
Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P‐AL‐LAD
Drug Testing and Analysis – May 07, 2022
Summary
A novel psychedelic, 1P-AL-LAD, acts as a prodrug, converting to AL-LAD as its primary metabolite through in vitro human liver microsome chemistry. This metabolism is crucial for its in vivo hallucinogen effects. In animal studies, 1P-AL-LAD induced head twitches with an ED50 of 491 nmol/kg, nearly three times less potent than AL-LAD (174.9 nmol/kg). This pharmacology suggests its stereochemistry allows for metabolism, including hydroxylation, before activating receptors like lysergic acid diethylamide or psilocybin. Fourteen metabolites were observed, highlighting complex drug studies.
Abstract
Abstract Lysergic acid diethylamide (LSD) is known to induce powerful psychoactive effects in humans, which cemented its status as an important too...
Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine—A Systematic Review and Meta-Analysis
Psychoactives – October 04, 2024
Summary
Psilocybin rapidly and sustainably reduced depressive and anxiety symptoms, a compelling finding from a meta-analysis of psychedelic drug studies. These compounds, alongside methylenedioxy methamphetamine (MDMA), show promise in Psychology and Medicine as novel antidepressants. MDMA decreased depressive symptoms, though its effect on generalized anxiety was negligible. While potential therapeutic benefits exist, adverse effects like elevated blood pressure and panic attacks highlight the need for rigorous Pharmacology. Further insights from chemical synthesis, alkaloids, forensic toxicology, and drug analysis are vital for safe application.
Abstract
Background: There is ongoing research into the potential use of psychedelics and 3,4-methylenedioxy-methamphetamine (MDMA) as alternatives to commo...
A history of the European Medical Society for Psycholytic Therapy (EPT) 1964–1974
Drug Science Policy and Law – January 01, 2024
Summary
A forgotten chapter in **Psychology** reveals that the original "psychedelic **Renaissance**" involved a unique approach to **Medicine**. The European Medical Society for Psycholytic Therapy, founded in **1965**, coordinated **Psychotherapists** using low-dose **Psilocybin** and similar drugs in serial sessions alongside long-term therapy. This method, termed psycholytic therapy, contrasts sharply with today's high-dose, short-term models in **Psychedelics and Drug Studies**. Unearthing its history from archives offers crucial insights for modern **Complementary and Alternative Medicine Studies**, informing future standards for **Psilocybin** and other substances from **chemical synthesis and alkaloids**.
Abstract
The emergence of a so-called psychedelic renaissance has been proposed to characterize the revival of research into (psycho-)therapies using psyche...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
Historical overview
OpenAlex – March 01, 2023
Summary
Human history with Psilocybin and Lysergic acid diethylamide is profound. Indigenous cultures used these hallucinogens for millennia, an ethnology now informing modern understanding. Albert Hofmann synthesized Lysergic acid diethylamide in the 1940s; Psilocybin gained notice in the 1950s, sparking cultural fascination, impacting art and art history. After 1970s drug laws, a 1990s scientific Renaissance began. Psychedelics and Drug Studies now explore their potential, much like a MAGIC telescope explores the cosmos, revealing new perspectives on this complex history.
Abstract
Abstract Humans have a long and complicated history with psychedelic compounds. Originally discovered as a component of certain plants and fungi, t...
Chapter 51. Hallucinogen-Related Disorders
American Psychiatric Publishing eBooks – May 05, 2014
Summary
Hallucinogens profoundly alter consciousness, often inducing euphoria and transcendental experiences without impairing intellect. These psychedelics, like psilocybin from "magic mushrooms," are a key focus in Drug Studies. Plant-based Medicinal Research investigates their natural origins, while Biochemical Analysis and Sensing Techniques illuminate their impact on psychology and psychiatry. Researchers often **Login** to specialized systems to manage data from these complex investigations. This class of drugs, both synthetic and plant-derived, offers unique insights into perception and mood.
Abstract
The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well...
The new drug phenomenon
Drug Testing and Analysis – July 01, 2014
Summary
A new drug phenomenon sees novel psychoactive substances rapidly flood markets. Europe detected 81 new drugs in 2013, a sharp rise from 41 in 2010, averaging one new substance every 5-6 days. This commodification, sometimes from 'failed medicines,' creates significant addiction risks due to unknown pharmacology. Forensic toxicology and drug analysis face immense challenges. The political science of control struggles against this tide, raising engineering ethics concerns about substances influencing neurotransmitter receptors, often explored in psychedelics and drug studies.
Abstract
This special issue provides a multidisciplinary snapshot of recent developments of the broader, arguably phenomenal, changes to the drug market tha...
Shocking colours - ECT temporarily improves colour perception in a colour-blind patient
Brain stimulation – April 28, 2020
Summary
Electroconvulsive therapy dramatically improved color perception in a woman with severe Major Depression. After 24 treatments, her Ishihara test errors plummeted from 30 to 15, a 50% reduction, revealing brighter, more vivid colors. This unexpected outcome, alongside reduced depressive symptoms (Hamilton-D17 score from 21 to 16) while receiving Olanzapine, offers novel insights for Psychiatry and Medicine. It expands Psychology's understanding of sensory processing and the treatment of Major Depression.
Abstract
Electroconvulsive therapy (ECT) is often the last resort in medically treatment-resistant patients. The mechanisms of its efficacy are still somewh...
THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE
PARIPEX INDIAN JOURNAL OF RESEARCH – May 15, 2023
Summary
Psychoactive substances like psilocybin, MDMA, and Ayahuasca show groundbreaking potential for mental health. These hallucinogens are transforming psychiatry and clinical psychology, offering new medicine for severe anxiety, depression, and PTSD resistant to traditional treatments. Research in Psychedelics and Drug Studies highlights their effectiveness, suggesting how their chemical synthesis and alkaloid nature influence behavior through neurotransmitter receptors. Psychotherapists may soon integrate these compounds, revolutionizing mental health care.
Abstract
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and ...
Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
Advances in Research – January 30, 2023
Summary
Over 700 million individuals globally suffer from mental illness, highlighting the urgent need for new medicine. Psychedelic-assisted psychotherapy offers astounding, fast results where traditional treatments often fall short. Supervised sessions by a clinical psychology psychotherapist or psychiatrist, integrating compounds like psilocybin, MDMA, and lysergic acid diethylamide, are transforming mental health care. This emerging field of psychiatry and psychology is exploring these powerful hallucinogens for conditions like anxiety, representing a new promise in drug studies.
Abstract
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted w...
Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey
PLOS mental health. – December 26, 2025
Summary
Autistic adults show strong interest in psychedelics for mental health support. A computer-assisted web interviewing survey of 261 autistic participants found 77.8% willing to try psychedelics like psilocybin for conditions such as anxiety, often addressed in clinical psychology. Remarkably, 69.7% reported past use, with higher doses correlating with lasting mental health improvements. Descriptive statistics underscore the need for inclusive psychiatry and mental health services, acknowledging autistic individuals' distinct needs compared to neurotypical populations in psychedelics and drug studies.
Abstract
Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress dis...
Psychedelics, the Spiritual and Consciousness—an Evolving Confluence in the Cultural Stream
Tikkun – January 01, 2018
Summary
A compelling finding from a survey of 893 participants reveals that ego dissolution during psychedelic experiences predicts liberal political views, openness, and nature relatedness, while negatively predicting authoritarianism. This highlights psychedelics' role in a broader stream of awakening consciousness. Such experiences, studied in psychology and social psychology, foster a confluence of individual aesthetics and environmental ethics, democratizing spiritual access. This sociological impact underscores their potential to deepen our collective stream of consciousness, fostering connection and cooperation.
Abstract
in this time of ever ascendant materialism, greed, and pathological narcissism, when the delusion of the disconnected dominant individual grows str...
Hair Analysis for Drugs of Abuse. X. Effect of Physicochemical Properties of Drugs on the Incorporation Rates into Hair.
Biological and Pharmaceutical Bulletin – January 01, 1995
Summary
Cocaine demonstrated the highest incorporation rate (ICR) into hair, with a staggering 3600-fold difference compared to THCA, which had the lowest ICR. The study evaluated 20 drugs, revealing that cocaine had the strongest affinity for melanin, followed by benzphetamine and phencyclidine. A notable correlation of 0.979 was found between ICRs and the combined factors of melanin affinity and lipophilicity. Basic drugs showed higher ICRs than neutral or acidic ones due to their membrane permeability influenced by the pH gradient between blood and hair matrix.
Abstract
To determine the mechanism involved, the incorporation rate (ICR) of drugs into hair was compared to melanin affinity, lipophilicity and membrane p...